Department of Biomorphology Sciences, Faculty of Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Cancer Cytopathol. 2010 Jun 25;118(3):157-65. doi: 10.1002/cncy.20046.
Thyroid fine-needle aspiration (FNA) samples belonging to the follicular neoplasm/suspicious for malignancy classes are controversial. The authors identified UbcH10 as a marker useful in the diagnosis of several neoplasms, including thyroid cancer. Here, analysis of UbcH10 expression by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemistry was applied to FNAs.
A series of 84 follicular neoplasm/suspicious for malignancy FNAs with histological follow-up (30 malignant) was prospectively collected. UbcH10 immunostaining was performed on cell blocks and compared with that of the proliferation marker Ki-67. At the mRNA level, UbcH10 was compared with CCND2 and PCSK2 expression, these latter being the best performing components of the previously reported 3-gene assay; to determine the diagnostic accuracy, the area under the curve (AUC) of the receiver operating characteristic (ROC) curve for each gene individually and in combination was evaluated.
UbcH10 and Ki-67 shared a similar pattern; although UbcH10 expression was higher in malignant than in benign lesions (P < .001), staining was sporadic, and the cutoff value derived by the ROC analysis was too low (1.25%) for routine application. Conversely, UbcH10 expression assessment by quantitative RT-PCR was effective. UbcH10 mRNA levels associated with malignant histology were significantly higher than those associated with benign histology (P = .02). The AUC was 0.74 for UbcH10, 0.81 for CCDN2, 0.62 for PCSK2, and 0.84 for UbcH10 and CCND2 combination.
UbcH10 quantitative RT-PCR analysis, rather than immunohistochemistry, is useful to increase the detection of malignancy in thyroid FNAs. UbcH10 may be added as a panel component in quantitative RT-PCR-based assays.
甲状腺细针抽吸(FNA)样本属于滤泡性肿瘤/疑似恶性肿瘤类别,存在争议。作者发现 UbcH10 是一种对多种肿瘤(包括甲状腺癌)诊断有用的标志物。在此,通过定量逆转录聚合酶链反应(RT-PCR)和免疫组织化学分析对 FNA 中 UbcH10 的表达进行了分析。
前瞻性收集了一系列具有组织学随访的 84 例滤泡性肿瘤/疑似恶性肿瘤 FNA(30 例恶性)。对细胞块进行 UbcH10 免疫染色,并与增殖标志物 Ki-67 进行比较。在 mRNA 水平上,UbcH10 与 CCND2 和 PCSK2 的表达进行了比较,后两者是之前报道的 3 基因检测中表现最好的成分;为了确定诊断准确性,分别评估了每个基因以及组合的接收器操作特征(ROC)曲线下面积(AUC)。
UbcH10 和 Ki-67 具有相似的模式;尽管恶性病变中的 UbcH10 表达高于良性病变(P<0.001),但染色呈散在性,ROC 分析得出的截断值(1.25%)太低,不适合常规应用。相反,通过定量 RT-PCR 评估 UbcH10 表达是有效的。与良性组织学相关的 UbcH10 mRNA 水平明显高于与恶性组织学相关的 UbcH10 mRNA 水平(P=0.02)。UbcH10 的 AUC 为 0.74,CCND2 为 0.81,PCSK2 为 0.62,UbcH10 和 CCND2 组合为 0.84。
UbcH10 定量 RT-PCR 分析而不是免疫组织化学分析可有助于提高甲状腺 FNA 中恶性肿瘤的检出率。UbcH10 可作为基于定量 RT-PCR 的检测面板的组成部分添加。